NTRS
35
10
SPG
45
2
NWSA
69
4
AMG
33
-11
DOW
47
4
GD
42
4
JNJ
30
4
MDT
59
4
M
40
3
EQIX
59
2
MSFT
55
2
URBN
67
3
PX
56
3
A
43
2
AMT
30
2
COF
48
3
AIG
38
5
HES
49
2
ADP
57
2
MO
47
6
NTRS
35
10
SPG
45
2
NWSA
69
4
AMG
33
-11
DOW
47
4
GD
42
4
JNJ
30
4
MDT
59
4
M
40
3
EQIX
59
2
MSFT
55
2
URBN
67
3
PX
56
3
A
43
2
AMT
30
2
COF
48
3
AIG
38
5
HES
49
2
ADP
57
2
MO
47
6
Financhill
Back

Ascendis Pharma AS 10K Form

Sell
43

ASND
Ascendis Pharma AS

Last Price:
$136.20
Seasonality Move:
19.34%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ASND News And Ratings

See the #1 stock for the next 7 days that we like better than ASND

ASND Financial Statistics

Sales & Book Value

Annual Sales: $288.8M
Cash Flow: $-110.6M
Price / Cash Flow: 0
Annual Sales: $-1.82
Price / Book: 0

Profitability

EPS (TTM): -8.10500
Net Income (TTM): $-462.8M
Gross Margin: $240.7M
Return on Equity: 0%
Return on Assets: -48.84%

Ascendis Pharma AS Earnings Forecast

Key Ascendis Pharma AS Financial Ratios

  • The Gross Profit Margin over the past 5 years for ASND is 83.36%.
  • The Selling, General & Administrative Expenses for ASND have been equal to 99.13% of Gross Profit Margin.
  • The Research & Development expenses have been 155.02% of Revenue.
  • The Interest Expense is -9.15% of Operating Income.
  • The Net Earning history of ASND is -180.51% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 4 years.

Ascendis Pharma AS Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ASND
CUSIP: 04351P
Website: ascendispharma.com

Debt

Debt-to-Equity Ratio: -8.1
Current Ratio: 1.16
Quick Ratio: 0.81

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ASND Technical Analysis vs Fundamental Analysis

Sell
43
Ascendis Pharma AS (ASND) is a Sell

Is Ascendis Pharma AS a Buy or a Sell?